China’s SFDA Proposes ‘Blacklist’ to Publicly Shame Drugmakers Into Higher Quality Standards

Clearly feeling the sting of the chromium-contaminated drug capsule scandal, China’s State Food and Drug Administration (SFDA) is proposing to draw up a “blacklist” of executives that oversee pharmaceutical companies in China found to produce substandard or counterfeit drugs. The list of offending executives would be made public and would detail their respective companies’ transgressions down to the unit level, according to a draft of the blacklist proposal recently released by the agency. The SFDA is taking public comment on the proposal through June 6.
Drug Industry Daily